Gan & Lee Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Gan & Lee Pharmaceuticals şirketinin toplam hissedar öz sermayesi CN¥11.2B ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥12.2B ve CN¥1.0B dir. Gan & Lee Pharmaceuticals 'in FAVÖK'ü CN¥249.6M faiz karşılama oranı -2 dur. Şirketin CN¥5.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	-2x
Nakit	CN¥5.07b
Eşitlik	CN¥11.21b
Toplam yükümlülükler	CN¥1.01b
Toplam varlıklar	CN¥12.22b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Sep 04

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Apr 29

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Mar 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 603087 'nin kısa vadeli varlıkları ( CN¥6.5B ) kısa vadeli yükümlülüklerini ( CN¥806.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 603087 şirketinin kısa vadeli varlıkları ( CN¥6.5B ) uzun vadeli yükümlülüklerini ( CN¥208.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 603087 borçsuzdur.

Borcun Azaltılması: 603087 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 603087 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 603087 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Gan & Lee Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Gan & Lee Pharmaceuticals. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 18%

Gan & Lee Pharmaceuticals. (SHSE:603087) announces an Equity Buyback for CNY 300 million worth of its shares.

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Gan & Lee Pharmaceuticals. to Report First Half, 2024 Results on Aug 29, 2024

Price target increased by 7.8% to CN¥62.50

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Investor sentiment deteriorated over the past week

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

New 90-day high: CN¥174

Investor sentiment improved over the past week

New 90-day high: CN¥136

New 90-day low: CN¥115

Third quarter earnings released

Earnings released

Gan & Lee Pharmaceutical, Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Gan & Lee Pharmaceutical, Ltd. announced that it has received funding from Hillhouse Capital Management, Ltd.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin